作者：行情君 从中证香港生物科技主题指数持仓样本的行业来看，化学药占比40.88%、生物药品占比39.81%、制药 与生物科技服务占比16.53%、医疗器械占比2.77%。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交易日。权重因子随样本定期调整而调整，调整时间与指数样本定期调整实施时间相同。在下一个定期 调整日前，权重因子一般固定不变。特殊情况下将对指数进行临时调整。当样本退市时，将其从指数样 本中剔除。样本公司发生收购、合并、分拆等情形的处理，参照计算与维护细则处理。 从指数持仓来看，中证香港生物科技主题指数十大权重分别为：百济神州（13.72%）、信达生物 （12.08%）、药明生物（9.08%）、康方生物（8.04%）、中国生物制药（6.18%）、石药集团 （5.78%）、三生制药（4.55%）、翰森制药（3.4%）、药明康德（2.82%）、科伦博泰生物-B （2.45%）。 从中证香港生物科技主题指数持仓的市场板块来看，香港证券交易所占比100.00%。 本文源自：金融界 金融界7月21日消息，上证指数高开高走，中证香港生物科技主题指数 (港股生物 ...

Core Insights - The AI Fund Qianhai Kaiyuan Medical Health A (005453) reported a profit of 57.04 million yuan for Q2 2025, with a weighted average profit per fund share of 0.123 yuan. The fund's net value growth rate was 12.63%, and the fund size reached 498 million yuan by the end of Q2 2025 [2][15]. Fund Performance - As of July 18, 2025, the fund's one-year cumulative net value growth rate was 47.58%, ranking 52 out of 133 comparable funds. Over the past three months, the growth rate was 39.80%, ranking 25 out of 138 [3]. - The fund's three-year Sharpe ratio was -0.3238, ranking 99 out of 105 comparable funds [8]. - The maximum drawdown over the past three years was 51.82%, with the highest quarterly drawdown occurring in Q3 2021 at 27.66% [10]. Investment Strategy - The fund focuses on flexible allocation, primarily investing in pharmaceutical and healthcare stocks. In Q2 2025, it emphasized investments in high-growth biotech companies and traditional pharmaceutical firms entering a harvest phase for innovative drugs. The fund manager anticipates continued demand for innovative drugs from overseas pharmaceutical companies due to the overseas patent cliff, alongside a surge in domestic supply of innovative drugs [2]. - The fund aims to enhance its research on industry fundamentals and macro trends, employing both top-down and bottom-up analysis methods for sector allocation and individual stock valuation assessments [2]. Fund Holdings - As of Q2 2025, the top ten holdings of the fund included companies such as Sanofi Pharmaceutical, Diligent Pharma, Innovent Biologics, and BeiGene, among others [18]. Fund Positioning - The average stock position over the past three years was 90.14%, with a peak of 93.11% at the end of H1 2025 and a low of 65.37% at the end of H1 2019 [13].

Core Viewpoint - The report highlights the strong performance of the Dongwu Medical Services Stock A fund, driven by the innovation drug sector, with a significant net value growth rate and positive returns over various time frames [2][3]. Fund Performance - In Q2 2025, the fund reported a profit of 8.0949 million yuan, with a weighted average profit per fund share of 0.106 yuan [2]. - The fund's net value growth rate for the reporting period was 18.12%, and as of the end of Q2, the fund size was 52.522 million yuan [2][15]. - As of July 18, the fund's unit net value was 0.822 yuan, with a one-year cumulative net value growth rate of 75.56%, ranking it 8th out of 53 comparable funds [2][3]. Investment Strategy - The fund focuses on long-term investments in pharmaceutical and medical stocks, with a portfolio primarily composed of innovative drugs [2][3]. - The fund manager noted that despite market volatility due to international trade impacts, the innovative drug sector quickly rebounded, reflecting confidence in the industry's trends [2]. Comparative Performance - The fund's three-month net value growth rate was 47.93%, ranking 5th out of 54 comparable funds, while the six-month growth rate was 69.65%, ranking 8th out of 54 [3]. - Over the past three years, the fund's Sharpe ratio was -0.0279, ranking 21st out of 46 comparable funds [8]. - The maximum drawdown over the past three years was 51.61%, with the largest single-quarter drawdown occurring in Q3 2022 at 24.3% [10]. Portfolio Composition - As of Q2 2025, the fund's top ten holdings included companies such as Innovent Biologics, CanSino Biologics, and 3SBio, indicating a high concentration in its stock holdings [17]. - The average stock position over the past three years was 85.43%, with a peak of 91.31% at the end of Q3 2022 and a low of 78.09% at the end of Q1 2023 [13].

Macro and Strategy - The macroeconomic report indicates a seasonal rebound in high-frequency indicators, with consumer performance remaining strong. The domestic economic growth momentum is improving, as evidenced by the positive shift in the macro diffusion index [8][9] - The report predicts an upward trend in the ten-year government bond yield and a downward trend in the Shanghai Composite Index for the week of July 25, 2025 [8] Industry and Company - The electric power equipment and new energy sector is expected to see increased demand for distribution equipment due to the approval of China's first cross-regional green electricity direct connection project [24] - The securities industry is experiencing a revival in equity refinancing, with several firms announcing plans to raise capital to support business expansion and innovation [26][27] - In the telecommunications sector, companies like Zhongji Xuchuang and Xinye Sheng are forecasting significant profit growth for the first half of 2025, driven by demand for high-speed optical modules [28] - Dongfang Electric is poised to benefit from the commencement of the Yarlung Zangbo River downstream hydropower project, with expected profit growth in the coming years [32] - Teruid's performance is projected to grow rapidly, with a forecasted net profit increase of 50%-80% for the first half of 2025, supported by strong overseas expansion [34][35] Financial Engineering - The convertible bond market is seeing strong demand for allocation, with a notable increase in the average price of convertible bonds and a decrease in the average conversion premium [13][14] - The report highlights the performance of various sectors, with semiconductor products and equipment, automotive, and software sectors receiving significant capital inflows [20][21]

Group 1: Fund Performance and Trends - The Dachen Insight Advantage Mixed Fund announced a successful launch with a total issuance scale of 2.46 billion, making it the largest actively managed equity fund launched in 2023 [1] - The Huashang Zhiyuan Return Mixed Fund also launched with a scale of 2.082 billion, setting a record for similar products this year [1] - The total issuance scale of actively managed equity funds reached 56.964 billion, reflecting a year-on-year growth of 28.01% compared to the same period in 2024 [1] Group 2: ETF Market Developments - The first batch of Sci-Tech Bond ETFs saw significant inflows, with the Huaxia ETF surpassing 14.2 billion in scale and experiencing a net inflow of approximately 11.1 billion on its first trading day, marking a 378% increase [2] - The Penghua Sci-Tech Bond ETF also reported a trading volume of 18.361 billion, with a turnover rate of 612.17%, bringing its scale to over 10.9 billion [2] - Among the four Sci-Tech Bond ETFs listed on the Shenzhen Stock Exchange, two have exceeded 10 billion in scale, namely the Jiashi and Fuguo Sci-Tech Bond ETFs [2] Group 3: Fund Liquidation - A total of 50 actively managed equity funds have been liquidated this year, including several initiated funds [3] - In July alone, six actively managed equity funds entered liquidation, triggered by the automatic termination of fund contracts without the need for a shareholder meeting [3] - Notable liquidated funds include those focused on popular sectors such as artificial intelligence and healthcare [3] Group 4: Floating Fee Rate Funds - The first batch of floating management fee funds has seen a total issuance scale of 24.762 billion, with 25 products announced as established [4] - A second batch of 11 floating fee rate funds has been submitted for approval, focusing on sectors like high-end equipment and healthcare [4] Group 5: Fund Manager Adjustments - Fund manager Liu Gesong has made significant adjustments in the second quarter, reducing holdings in the new energy vehicle supply chain and semiconductor equipment companies while increasing positions in new consumption, internet, and military industries [5] - Liu emphasized the importance of monitoring domestic and international economic developments and policy impacts on industries [5] Group 6: Portfolio Insights - Gao Nan, Chief Equity Investment Officer at Yongying Fund, has concentrated investments in TMT and innovative pharmaceutical sectors in his second-quarter report [6] - The top ten holdings of Gao's flagship fund include companies like Pop Mart, Zhongji Xuchuang, and Kangfang Biotech, with notable new additions and increased stakes in several stocks [7] Group 7: Market Overview - On July 18, the market showed mixed performance, with the Shanghai Composite Index rising by 0.5% and total trading volume reaching 1.57 trillion, an increase of 31.7 billion from the previous trading day [8] - Sectors such as rare metals and energy metals performed well, while gaming and consumer electronics sectors experienced declines [8]

Core Viewpoint - Gao Nan's managed funds reported significant growth in the second quarter, with a total management scale of 15.326 billion yuan, an increase of nearly 30% from the previous quarter [1] Fund Performance - Gao Nan's flagship fund, Yongying Ruixin, saw an increase of nearly 1.6 billion yuan in scale during the second quarter, reaching 5.016 billion yuan [1] - The net asset value of Yongying Ruixin Mixed A Fund was 1.4545 yuan at the end of the reporting period, with a net value growth rate of 10.12%, compared to a benchmark return of 1.50% [1] Portfolio Composition - The top ten holdings of Yongying Ruixin as of the end of the second quarter included Pop Mart (09992), Zhongji Xuchuang (300308), Kangfang Biotech (09926), Xinyi Sheng (300502), Jiangxin Home (301061), Xinda Biotech (01801), Weichai Heavy Industry (000880), Baijie Shenzhou (688235), San Sheng Pharmaceutical (01530), and Zijin Mining (601899) [1] - New additions to the portfolio included Zhongji Xuchuang, Xinyi Sheng, Xinda Biotech, Weichai Heavy Industry, San Sheng Pharmaceutical, and Zijin Mining, while Kangfang Biotech and Baijie Shenzhou were increased [3] Macroeconomic Environment - The overall economic operation in China remained stable in the second quarter, with resilient industrial production and high levels of infrastructure and manufacturing investment [3] - The central bank implemented measures such as reserve requirement ratio cuts and interest rate reductions to stabilize the market and expectations [3] Market Analysis - The Shanghai Composite Index rose by 3.26% in the second quarter, despite experiencing significant volatility [3] - The market saw a notable differentiation in asset performance, with sectors like innovative pharmaceuticals, artificial intelligence, and finance showing significant excess returns [3] Investment Strategy - The investment strategy emphasized bottom-up stock selection, focusing on company growth potential and earnings realization [4] - The fund aims to diversify industry concentration while capturing growth opportunities, and it also considers stocks with a safety margin and potential for future improvement [4]

Group 1 - The innovation drug and AI computing sectors showed strong performance, with related ETFs rising significantly, such as the Huatai-PB Hang Seng Innovation Drug ETF increasing over 13% [1][2] - The first batch of 10 Sci-Tech Bond ETFs launched on July 17, attracting nearly 60 billion yuan in net inflows over two trading days, increasing total scale from under 29 billion yuan to over 88 billion yuan [2][3] - Major pharmaceutical companies in China are expanding their business development efforts due to the upcoming patent cliff for multinational corporations, indicating a strengthening of China's innovation drug sector [1] Group 2 - The AI computing sector also performed well, with stocks like New Yisheng rising nearly 40%, and several ETFs in this space increasing over 10% [2] - Fund managers are applying for their Sci-Tech Bond ETFs to be included in the repurchase pledge library, which could enhance market liquidity and attract more long-term capital [3] - The leading broad-based ETFs experienced significant outflows, with a total net outflow of nearly 20 billion yuan for ETFs tracking major indices [3] Group 3 - The A-share market remains strong due to stable policy expectations, which have created a "buffer" against macroeconomic disturbances [4] - There is a focus on low-valuation cyclical stocks in the short term, while mid-term opportunities lie in sectors benefiting from supply-side improvements and policy support [4] - The outlook for the Chinese stock market is positive, driven by favorable policies and potential reallocation opportunities in sectors like AI and emerging industries [5]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of July 20, 2025 [1] Core Insights - The establishment of a positive innovation cycle is driving value enhancement in the pharmaceutical sector, particularly through overseas collaborations and the increasing recognition of the value of PD-1/VEGF dual antibodies [2] - The focus on tri-antibodies is rising, with significant potential for competition in first-line treatments, as evidenced by recent collaborations and promising clinical data [3] - The trend towards more effective and scientifically-backed weight loss solutions is evident, with GLP-1 drugs projected to generate over $50 billion in global sales in 2024, significantly boosting capital interest [5] - The trend in autoimmune drug development is shifting towards innovative therapies, with notable advancements in dual-target fusion proteins [6] - The approval of Vuxinib (伏欣奇拜单抗) marks a significant milestone in biological treatments for gout, with a substantial market potential due to the increasing prevalence of hyperuricemia and gout [7] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry outperformed the CSI 300 index by 2.91 percentage points in the past week, with a weekly increase of 4.00%, ranking second among 31 primary industry indices [19] - Over the past month, the pharmaceutical sector outperformed the CSI 300 index by 5.90 percentage points, with an increase of 11.51%, ranking fourth among primary industry indices [21] 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical sector has shown a 14.50% increase over the past six months, outperforming the CSI 300 index by 4.46 percentage points [36] - The current PE (TTM) for the pharmaceutical sector is 37.25, which is above the five-year historical average of 32.24 [39] 3. Recent Research Achievements - The research team has published several in-depth reports highlighting the positive trends in supply and demand within the pharmaceutical industry, including the growth of blood products and the acceleration of the import substitution process in inhalation preparations [44] 4. Recent Industry Policies and News - Recent measures from the National Medical Insurance Administration aim to support the high-quality development of innovative drugs, enhancing their market access and clinical application [46] - Notable industry news includes the approval of new indications for existing drugs and significant collaborations between major pharmaceutical companies [47][49]

Core Viewpoints - The pharmaceutical and biotechnology sector is experiencing a turning point and structural market trends in the first half of 2025, with a focus on innovative drugs and their supply chain, AI healthcare, and brain-computer interfaces as structural opportunities [3][5] - The A-share pharmaceutical and biotechnology index has increased by 10.10% since the beginning of 2025, outperforming the CSI 300 index by 8.90 percentage points, ranking 4th in industry performance [3][22] - Among 480 listed pharmaceutical and biotechnology companies, 348 have seen their stock prices rise, accounting for 72.5%, with 17 stocks doubling in value [3][40] Investment Logic - The innovative drug sector is accelerating its value reconstruction through business development (BD) overseas, research and commercialization progress, and policy support. In the first half of 2025, over 50 BD transactions for innovative drugs occurred, totaling over $48 billion [5] - Significant clinical data releases and commercialization progress for major drug candidates are expected to drive stock price increases [5] - Policy initiatives, such as the March 2025 government work report emphasizing the support for innovative drugs and medical devices, are providing strong backing for the industry's long-term development [5] Market Performance - The pharmaceutical sector's valuation has seen a short-term recovery but remains at a long-term low, with a PE ratio of 29 times as of mid-2025, slightly above the 50th percentile of the past four years [3][43] - Public fund holdings in the pharmaceutical sector have increased, with the proportion of public funds in A+H shares rising to 9.05% in Q1 2025, a 0.37 percentage point increase [3][58] Sub-industry Performance - The best-performing sub-industries in the pharmaceutical sector include chemical preparations and other biological products, with increases of 25.8% and 24.0%, respectively [3][22] - The pharmaceutical industry is witnessing a structural market trend, with innovative drugs leading the charge, while traditional sectors like vaccines and traditional Chinese medicine have seen slight declines [3][29] Recommended Stocks - A robust portfolio is suggested, including companies such as Heng Rui Medicine, BeiGene, and United Imaging Healthcare, among others [10]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry [1]. Core Insights - The autoimmune disease sector is entering the era of bispecific antibodies, with significant market potential and unmet treatment needs, projected to reach USD 119.35 billion by 2027 [4][16]. - The report highlights the advantages of bispecific antibodies in treating autoimmune diseases, including improved efficacy through dual-targeting mechanisms and reduced toxicity [20][21]. - The report suggests focusing on companies with promising bispecific antibody candidates in clinical stages, such as ZhiXiang JinTai, KangNuoYa, and KangFang Biotech [4][11]. Summary by Sections Industry Trends - The A-share pharmaceutical index has increased by 4.0% this week and 16.59% year-to-date, outperforming the CSI 300 by 2.9% and 13.45% respectively [9]. - The H-share biotechnology index has shown a year-to-date increase of 81.80%, outperforming the Hang Seng Technology Index by 56.88% [9]. Autoimmune Diseases Entering the Bispecific Era - Bispecific antibodies can target two different antigens simultaneously, providing enhanced therapeutic effects and addressing treatment resistance [17][20]. - The report discusses the competitive landscape for bispecific antibodies in treating conditions like COPD and IBD, emphasizing the need for better treatment options [4][10]. R&D Progress and Company Dynamics - The report notes the approval of HeYuan Biotech's recombinant human serum albumin, marking a significant milestone in the domestic market [4]. - It provides a detailed overview of ongoing clinical trials and product approvals, highlighting key players in the innovation drug sector [4][11]. Market Insights and Regulatory Dynamics - The report tracks the performance of various pharmaceutical sub-sectors, noting significant gains in raw materials and chemical pharmaceuticals [9]. - It emphasizes the importance of regulatory developments and market dynamics in shaping the industry's future [4][10]. Specific Investment Recommendations - The report ranks preferred sub-sectors as follows: innovative drugs > research services > CXO > traditional Chinese medicine > medical devices > pharmacies [10]. - Specific companies to watch include ZhiXiang JinTai, KangFang Biotech, and KangNuoYa for innovative drugs, and WuXi AppTec and Aopumai for research services [11][12].